SEC Filing Summary: Synta Pharmaceuticals Corp.
Business Context and Reporting Period
This Form 8-K was filed by Synta Pharmaceuticals Corp. on February 15, 2012, reporting events occurring on February 10, 2012. The registrant is a Delaware corporation headquartered in Lexington, MA. Note: The input metadata references "Madrigal Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Under Item 5.02, the company reported the departure of a director:
- Lan Bo Chen, Ph.D., notified the company of his intention to resign from the Board of Directors.
- The resignation is effective March 1, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of Dr. Chen's resignation (March 1, 2012).
- Confirm whether a replacement director has been nominated or elected to fill the vacancy.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.